Last reviewed · How we verify
omega-3-fatty acids (Omegaven)
Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways by competing with omega-6 fatty acids in cell membranes and serving as precursors for anti-inflammatory mediators.
Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways by competing with omega-6 fatty acids in cell membranes and serving as precursors for anti-inflammatory mediators. Used for Hypertriglyceridemia, Parenteral nutrition support in neonates and pediatric patients with intestinal failure, Cardiovascular disease prevention.
At a glance
| Generic name | omega-3-fatty acids (Omegaven) |
|---|---|
| Also known as | Omegaven |
| Sponsor | Li Shin Hospital |
| Drug class | Lipid-modifying agent; anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Omega-3 fatty acids (EPA and DHA) incorporate into cell membranes and displace omega-6 arachidonic acid, reducing production of pro-inflammatory eicosanoids. They also activate G-protein coupled receptors and nuclear receptors (PPAR-γ, LXR) that suppress inflammatory gene expression. Additionally, they lower hepatic triglyceride synthesis and VLDL production, improving lipid profiles.
Approved indications
- Hypertriglyceridemia
- Parenteral nutrition support in neonates and pediatric patients with intestinal failure
- Cardiovascular disease prevention
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Bleeding or increased bleeding tendency
- Fishy aftertaste
- Hypersensitivity reactions (with IV formulation)
Key clinical trials
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Effect of Parenteral Nutrition With n-3 PUFAs on Patients With Intestinal Failure (NA)
- Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity (PHASE2)
- Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - (PHASE2)
- Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants (NA)
- Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- omega-3-fatty acids (Omegaven) CI brief — competitive landscape report
- omega-3-fatty acids (Omegaven) updates RSS · CI watch RSS
- Li Shin Hospital portfolio CI